The Oncologist

CAMPTOSAR®
irinotecan HCl injection

First-line metastatic colorectal cancer therapy in combination with 5-FU/L

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Cancer Vaccines

Igor Espinoza-Delgado

Section of Hematology-Oncology, Gerontology Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland

Correspondence: Igor Espinoza-Delgado, M.D., Section of Hematology-Oncology, Gerontology Research Center, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Drive, Room 4C10, Baltimore, Maryland 21224, USA. Telephone: 410-558-8190; Fax: 410-558-8284; e-mail: espinozaig@grc.nia.nih.gov.

- Abstract of this Article
- **Reprint (PDF) Version of this Article**
- **CME:** Take the course for this article: Cancer Vaccines
- Similar articles found in: The Oncologist Online PubMed
- PubMed Citation
- Search Medline for articles by: Espinoza-Delgado, I.
- Download to Citation Manager

▶ LEARNING OBJECTIVES

After completing this course, the reader will be able to:

1. Explain the relationship between the tumor and host immune system.
2. Recognize the mechanisms by which tumor cells escape the immune surveillance.
3. Recognize the potential of vaccines in the treatment and prevention of cancer.

Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com

▶ ABSTRACT

Although cancer immunotherapy was initiated by *William Coley* more than a century ago, the field of cancer vaccines is in an early stage of development. Only recently, major advances in cellular and molecular immunology have allowed a comprehensive understanding of the complex and high rate of interactions between the immune system and tumor cells. We have learned that these tumor–immune system interactions may result either in strong immune antitumor response or tolerance to tumor-associated antigens. This article will discuss the profound interest in cancer vaccines derived from their potential to induce antitumor responses in vivo. Substantial data from several preclinical

models and early human clinical trials have confirmed the ability of cancer vaccines to induce immune responses that are tumor-specific and, in some cases, associated with clinical responses. One future challenge will be to determine how to appropriately stimulate the pathways leading to effective interaction among antigen-presenting cells, T lymphocytes, and tumor cells. It also is critical to develop monitoring strategies that may allow the identification of patients who may benefit from cancer vaccines.

Key Words: Cancer· Vaccines· Immunotherapy· Dendritic cells

▶ INTRODUCTION

The observation that some human tumors experience spontaneous regression suggests that the immune system may have the potential to protect against the uncontrolled growth of cells that have undergone neoplastic transformation [1, 2]. Central to this long-held basic paradigm of immunology is the ability of the immune system to recognize tumor-associated antigens (TAA) displayed on human malignancies and to direct cytotoxic responses to these targets. These recognizable antigens may range from short, three-dimensional structures that are identified by antibodies to even smaller amino acid sequences that are discernible by cytotoxic T lymphocytes (CTLs) [3–6].

Although antibodies alone or in combination with chemotherapy can be highly effective in mediating tumor regression in hematologic malignancies [7–10], their effects on solid tumors have been less effective. Moreover, most responsive solid tumors are malignancies that overexpress certain growth factor receptors [11]. T-cell-mediated immune responses seem to have a greater potential for eradicating tumor cells. Therefore, a significant amount of preclinical and clinical research is focused on inducing a cellular antitumor immune response, and one of the main goals of cancer immunotherapy is to generate highly specific CTLs.

Several clinical trials of immunotherapy in cancer patients have attempted to activate the immune system in an effort to elicit an effective antitumor response. The majority of these clinical trials focused on the effector phase of the immune response, specifically the activation and/or generation of cells with cytotoxic capabilities such as natural killer (NK) cells, lymphokine-activated killer cells, and tumor-infiltrating lymphocytes. It is clear from trials using interleukin-2 (IL-2) that immune manipulation can induce durable major responses or even cure a subset of patients with extensive metastatic renal carcinoma or melanoma [12–15].

Generation of CTLs is a complex process that requires a minimum of two signals. The first signal, recognition, is mediated by interaction of the T-cell receptor with a specific antigenic peptide presented on the antigenpresenting cell (APC) in the context of the HLA, the human major histocompatibility complex (MHC) [16]. The second signal, costimulation, is delivered by APCs through members of the B7 family and various adhesion molecules [17–20] (Fig. 1A▣). If costimulation is not administered, T

cells may enter a state of anergy [20–23], which may result in tolerance to tumor antigens and failure to halt tumor growth (Fig. 1B⊞). It is noteworthy that in tumor-bearing hosts, TAA are presented either by APCs or tumors themselves in a fashion in which costimulation and/or other critical signals to T cells are not effectively delivered [24–26]. Thus, the default response of the immune system after interacting with tumor cells is anergy and consequently the development of tolerance. The present challenge for the immunotherapy of cancer is to overcome the barriers that prevent the appropriate recognition and elimination of neoplastic cells.

View larger version (21K):
[in this window]
[in a new window]

Figure 1. T-cell activation by antigen-presenting cells requires a close APC–T-cell interaction and the delivery of recognition and costimulatory signals (A). T-cell anergy occurs when the recognition signal is given in the absence of costimulation (B).

▶ CANCER VACCINES

Tumor–Host Interaction

Tumor cells are genetically unstable and do not have efficient mechanisms that protect against this instability [27–29]. As a result, a small percentage of tumor cells will undergo apoptosis and release apoptotic bodies containing TAA that are taken up by immature APCs. In the presence of the appropriate cytokine microenvironment, immature APCs may become mature APCs and deliver costimulation signals resulting in the generation of T cells with an activated phenotype. Activated CD4 cells produce an array of cytokines leading to the generation and clonal expansion of TAA-specific CTLs that will recognize and

kill tumor cells (Fig. 2⊞). Unfortunately, cancer cells, under the selective pressure of the immune system, have developed mechanisms allowing them to avoid being targeted by the immune system (Table 1⊞). Furthermore, tumor cells, in sharp contrast with bacteria or viruses, do not induce the proinflammatory cytokines and chemokines required for the proper interaction between APCs and antigen-specific reactive T cells [30–32].

Figure 2. Potential interactions between the tumor and the immune system. Apoptotic bodies derived from tumor cells are taken up and processed by immature APCs. Upon maturation, APCs deliver recognition and costimulatory signals to CD4 T cells in the presence of cytokines that favor the development of CTLs. By producing factors that interfere with the maturation process of APCs and the delivery of recognition and costimulatory signals, tumor cells may affect

the generation of CTLs and escape the immune response.

View larger version (53K):
[in this window]
[in a new window]

View this table: **Table 1.** Potential barriers to cancer vaccine: tumors escape the immune
[in this window]   system
[in a new window]

Pioneering studies performed by *Dr. William Coley* more than 100 years ago clearly established the curative potential of bacteria and bacteria lysates in patients with cancer [33, 34]. It is now known that *Coley's* toxin was not directly responsible for the antitumor effects observed. Rather, some of the bacterial products, which were very potent at activating the immune system, destroyed the tumors [35]. Decades later, *Tokunaga et al.* demonstrated that bacterial DNA alone could account for the immunomodulatory and antitumor properties of BCG [36]. More recently, studies with antisense oligodeoxynucleotides (ODN) revealed that CpG dinucleotides were potent stimulators of B cells [37], NK cells [37], and APCs [38, 39]. Furthermore, CpG DNA induces innate immune resistance to tumors as well as the regression of established tumors in mice [40, 41]. Many investigators are now using cancer vaccines to overcome some of the barriers to successful cancer immunotherapy by mimicking the proinflammatory responses generated by the innate immune system when exposed to tissue-destructive viral and bacterial infections. The ultimate goal of vaccine strategies is to convert a tolerant T cell to a fully aware and activated TAA-specific T cell that would be the most effective antitumor effector cell.

Based on preclinical and clinical research, a large number of cancer vaccine clinical trials involving different tumor types and various vaccine strategies currently are being conducted. The increasing number of TAA (Table 2▣) and strategies (Table 3▣) prevents detailed discussion of all the clinical information available. Melanoma is one of the best-studied malignancies in the cancer immunology field, and almost all existent immunotherapy strategies have been tested in patients with this disease because it is one of the human malignancies to which immune responses can be demonstrated consistently. Therefore, using melanoma as a model, we will discuss some of the vaccine approaches available for the treatment of cancer. We also will discuss other diseases with unique characteristics not commonly found in melanoma.

View this table: **Table 2.** Potential targets for cancer vaccines
[in this window]
[in a new window]

View this table: **Table 3.** Cancer vaccines: strategies
[in this window]
[in a new window]

▶   PEPTIDES AND PROTEINS

▲ **Top**
▲ **Learning Objectives**
▲ **Abstract**
▲ **Introduction**
▲ **Cancer Vaccines**
▪ **Peptides and Proteins**
▼ **Gangliosides**
▼ **Cellular Vaccines**
▼ **Tumor-APC Hybrids**
▼ **Idiotype Vaccination**
▼ **Conclusions**
▼ **References**

The development of therapies specifically targeting TAA has the advantage that the immune response would be directed mainly against the tumor cells and few other normal tissues. However, one potential major disadvantage of peptide vaccines is the possibility of raising an irrelevant peptide-specific response. For instance, it was reported that patients immunized with her2 peptide developed her2-specific T-cell responses; however, the reactive T cells failed to recognize her2+ tumor cells [42, 43]. This suggests that the peptide may not be processed naturally by the tumor cell. This disadvantage is of particular concern when using tailored peptides from patient-specific mutated proteins, i.e., p53 and ras. Several melanoma antigens have been identified and generally could be classified into cancer testes antigens [44–46], differentiation antigens [47–51], and mutated antigens or atypical transcripts antigens [52–54] (Table 2▣). The cloning of the genes encoding cancer antigens has provided new possibilities for cancer treatment.

Vaccine trials using some of the aforementioned antigens recently have begun and are providing substantial information about the type of immune responses that are elicited. These studies are in relatively early stages and only a few vaccines have entered later stages of clinical testing. Although current results are not final, some conclusions can be drawn. First, CTL responses can be induced by peptide vaccination [43, 55, 56]; second, the presence of an expanded pool of TAA-specific T cells does not lead to tumor regression [57–59]; third, increasing the affinity of the peptide for the MHC can greatly increase the potency of a vaccine by converting a subdominant epitope into a dominant one [4, 60, 61]. Using a modified gp100 peptide, *Rosenberg et al.* elicited peptide-induced T-cell responses in 91% of patients immunized. In contrast, vaccination with the unmodified peptide failed to induce a T-cell response in most patients [4]. Lastly, peptide-based vaccinations by themselves have not demonstrated clinical efficacy unless combined with IL-2 administration. In fact, a clinical trial conducted at the National Cancer Institute (NCI) reported that administration of high-dose IL-2 following s.c. administration of the modified peptide resulted in a clinical response of 42%, whereas no clinical responses were observed in patients receiving the modified peptide alone. Curiously, however, patients who achieved clinical response had a decreased T-cell response. The authors believed that the

decreased response was due to homing of the reactive T cells to the tumor site [4]. Randomized clinical studies are currently under way at the NCI to ascertain the contribution of each component of the treatment to the observed response.

GANGLIOSIDES

Immunizations with nonpeptide antigens also have been used against melanoma. Gangliosides are sialated glycolipid antigens expressed on normal cells of neural crest origin and highly expressed on melanoma. Among the gangliosides, GM2 has been found to be the most immunogenic and has been the target of several vaccination clinical trials in the adjuvant setting for patients with melanoma at high risk for recurrence. For example, a double-blind randomized clinical trial in patients with resected stage III melanoma compared patients treated with GM2/BCG with patients receiving BCG alone. The study demonstrated that immunization with GM2/BCG induced GM2 antibody in 64% of patients, while only 11% of patients treated with BCG alone developed antibodies. The antibody production was associated with prolonged disease-free interval (DFI) and survival. However, there were no statistically significant differences between treatments in either DFI or survival [62]. This study led to the design of a large prospective, randomized, intergroup trial evaluating high-dose interferon-α2b (IFN-α2b) (HDI) versus vaccination with GM2 conjugated to keyhole limpet hemocyanin (KLH) and administered with QS-21 as adjuvant [63]. The trial had a median follow-up of 16 months and was closed after an interim analysis revealed the superiority of HDI compared with GM2 vaccination.

The idea of combining IFN-α2b and GM2 vaccinations is very appealing. However, there has been a concern that IFN-α could reduce the humoral response induced by the vaccine. A recent report by *Kirkwood et al.* specifically addressed this concern and reported that IFN-α combined with GM2 immunization does not decrease antibody response to GM2 vaccination [64]. The combination also seems to improve DFI; however, inasmuch as IFN-α2b alone was not tested, it is not known whether the benefit was due to IFN-α2b, or an additive or synergistic effect with the vaccine exists. Future randomized studies will address this question.

CELLULAR VACCINES

Patients with cancer have multiple alterations of the immune system that may compromise the recognition and elimination of tumor cells [65, 66]. Additionally, tumor cells by themselves may induce tolerance [67, 68]. These characteristics of both the immune system and the tumor cell likely contribute to tumor growth. One of the relatively new approaches to enhancing the antitumor response is to provide cells that may facilitate the creation of the proper microenvironment with the potential to overcome tumor-induced

tolerance. Cancer cellular vaccines can be packaged in at least three forms: 1) dendritic cells (DCs); 2) autologous or allogeneic tumor cells, and 3) tumor-APC hybrids. The cellular vaccines are manipulated ex vivo and then administered to patients via different routes. Cellular vaccines are in the early stages of development for cancer treatment and here we will summarize some of the approaches that have been taken to the clinic. We will not discuss approaches involving the use of recombinant DNA alone (naked DNA) or tumor RNA.

Dendritic Cells

Attempts to increase the efficacy of peptide vaccines have lead to the use of APCs as delivery vehicles and cellular adjuvants (Fig. 3⊞). DCs are professional APCs that play a crucial role in the initiation of the immune response through the uptake, processing, and presentation of tumor antigens to T cells. DCs have been described as the most potent and efficient APCs capable of activating both resting and naïve T cells [69, 70]. Preclinical studies have clearly demonstrated that antigen-pulsed DCs can generate protective immunity against tumors [71–73]. More recently, pilot studies performed in various types of cancer including melanoma [74–76], lymphoma [77, 78], multiple myeloma [79, 80], colon cancer [81], prostate cancer [82–86], and glioblastoma [87] suggest that monocyte-derived DCs are capable of eliciting antigen-specific immune responses in humans, some of which are associated with clinical responses. The majority of the clinical trials using the DC-based cancer vaccine approach have been performed in patients with metastatic melanoma. Although early studies using peptide-pulsed DC clearly demonstrated antigen-specific immune responses both to the immunizing peptide and to autologous tumor, no clinical responses were observed [75]. More recently, a better understanding of the biology of DCs and a major improvement in the culture and administration conditions of these cells have occurred, paving the way for more rationally designed clinical trials.

Figure 3. Adoptive immunotherapy with autologous monocyte-derived DCs. Peripheral blood mononuclear cells (PBMCs) are collected by leukopheresis. Monocytes are purified by elutriation and induced to differentiate into mature DCs with cytokines. Dendritic cells are then pulsed with peptides or tumor lysates and infused back to patients.

View larger version (53K):
[in this window]
[in a new window]

It is known now that the maturation stage of DCs is quite relevant. Whereas immature cells are better suited to take up and process antigens, mature DCs are better at presenting antigens [69]. Recently, *Nestle et al.* reported on a clinical trial involving 16 patients with metastatic melanoma who received a

DC-based cancer vaccine [76]. Twelve patients received DCs loaded with multiple melanoma-associated peptides (either HLA-A2-binding peptides such as tyrosinase, MART-1, and gp100 or HLA-A1-binding peptides such as MAGE-1 and MAGE-3), and four patients received tumor lysates instead of peptides. The rationale behind the use of multiple peptides or tumor lysates was to decrease the chances of the tumor escaping the immune response by acquiring single-point mutations. Because primary immune responses occur in lymphoid organs, *Nestle et al.* delivered the DC preparation (1×10^6 cells) into an inguinal lymph node or in close proximity to the regional lymph node. Patients were immunized once weekly for 4 weeks, followed by booster immunizations given after 2 weeks and thereafter in monthly intervals for up to 10 vaccinations. Treatment was well tolerated, with only occasional mild fever or swelling at the injection site that lasted 1 to 2 days. The use of self-antigens or tumor lysates has the potential of breaking tolerance and inducing autoimmunity. Although clinical evidence of autoimmunity was not observed, anti-thyroid stimulating hormone (TSH) receptor antibodies and antinuclear antibodies were detected in a few patients thus raising the need for caution. Eleven of 16 patients immunized with the DC preparation developed a positive delayed-type hypersensitivity (DTH) response. More importantly, regression of lesions in pancreas, lung, and skin were observed in six patients (two complete responses [CRs], three partial responses [PRs], and one minor response) with some responses lasting more than 15 months. The observed clinical responses were accompanied by antigen-specific reactivity. Two of five responders received DCs pulsed with tumor lysates in which the identity of the relevant TAA is not known. These results suggest that similar approaches could be used in the setting of tumors lacking well-characterized antigens.

Although the study of *Nestle et al.* is clearly relevant, the small number of patients limits the conclusions that can be drawn. Nevertheless, this pilot study demonstrates that DC-based cancer vaccines must be further explored to define the best strategies to be used with this approach. Several variables should be evaluated, including: 1) the type of DC to be used; 2) the type of adjuvant; 3) the cytokine(s) to be administered, and 4) the method of providing TAA, i.e., peptides, tumor lysates, RNA, DNA, etc. Significant clinical effort and time will be required to answer these fundamental questions.

Tumor Cells

Autologous and allogeneic tumor cells were one of the first types of tumor vaccines to be used [88–90]. Theoretically, the main advantage of tumor cell vaccines is that they have all the relevant tumor antigens needed by the immune system to mount an effective antitumor response. This is particularly true if autologous tumor cells are used instead of allogeneic tumor cells. A second advantage is that tumor cell-based immunization allows the development of cancer vaccines without knowing the specific antigens. The advantages of tumor cell-based cancer vaccines must be balanced against two major disadvantages: the potential for autoimmunity and the potential for increasing the anergic status of the T cells due to the lack of functional costimulatory molecules on tumor cells.

Initial attempts to immunize cancer patients with tumor cells were disappointing [88–90] and temporarily decreased interest in the field. The lack of effectiveness could be explained by the inability of tumor cells to create an inflammatory response that attracts APCs to the tumor site where they could take up, process, and present TAA to T cells within the context of the MHC and in the presence of the

constitutively expressed costimulatory molecules. To test whether the addition of nonspecific bacterial adjuvants could improve the outcome of this approach, a prospective randomized trial was conducted in patients with Duke's stage B and C colon cancer [91]. Four weeks after surgery, 254 patients were randomly assigned to receive autologous vaccine plus BCG or no adjuvant treatment. Three weekly vaccinations were given followed by a booster vaccination at 6 months. Patients with Duke's stage B disease who received the vaccine had a significant improvement in recurrence-free survival ($p = .0032$) compared with patients who did not receive the vaccine. There was no benefit for patients with Duke's stage C disease.

More recently, a phase III clinical trial with a similar cohort of patients was conducted by the Eastern Cooperative Oncology Group [92]. In this study, 412 patients (297 with stage II disease and 115 with stage III disease) were randomized to receive intradermal vaccine injections or no vaccine three times weekly 4 weeks after surgery. After a 7.6-year median follow-up period, there were no significant differences in clinical outcomes between the two arms. However, subset analysis, with all its caveats and pitfalls, revealed that patients mounting a potent DTH to the vaccine have a 5-year survival advantage compared with patients who did not have a DTH. Taken together, these studies suggest that a subset of patients may benefit from autologous colon cancer vaccines. They also suggest that the addition of nonspecific adjuvants to autologous cancer vaccines has not resulted in a major breakthrough; therefore, other avenues have been explored.

In vitro and preclinical studies have provided evidence that genetically modified tumor cells display an increased immunogenicity [93–98]. The modifications are aimed to counteract some of the defects found in tumor cells that prevent them either from acting as professional APCs or being targeted by CTLs: low or undetectable MHC expression, lack of costimulatory molecules, and inability to produce cytokines required for DC maturation GM-CSF, IL-4, tumor necrosis factor [TNF]) or T helper (Th)1 polarization (IL-12). The knowledge generated from preclinical models has resulted in the development of several clinical trials [99–102]. The goals of these clinical trials are to evaluate the safety and define the toxicities associated with the administration of genetically modified tumor cells. Initial reports demonstrated that the approach is safe and associated with only minor local toxicities.

Simons et al. performed a randomized, double-blind, phase I clinical trial that evaluated the safety of and immune response to an autologous renal cell carcinoma (RCC) vaccine modified with the GM-CSF gene [100]. Eighteen patients received equivalent doses of irradiated autologous RCC cells with or without ex vivo human GM-CSF gene transfer. No dose-limiting toxicities were observed. Histopathology of the vaccine site at day 7 revealed that CD3$^+$ cells and DC infiltration were increased in the GM-CSF-transduced vaccine relative to the nontransduced cells. Furthermore, an intense eosinophil infiltrate was observed at the vaccine site of the transduced vaccine compared with the nontransduced vaccine. Interestingly, preclinical models have suggested that the eosinophil infiltrate is relevant and associated with antitumor immunity [103]. One patient had a PR with regression of multiple pulmonary metastases. Of note, this particular subject experienced intense pruritus at the vaccine site after receiving the third cycle of GM-CSF-transduced vaccine.

A major limitation of this trial and many others using autologous tumor cells is the low yield of autologous tumor cells that may compromise the number of immunizations given to the patients. A second inconvenience is the variability of GM-CSF secretion among patients, which could be responsible for the different levels of responses observed. Although autologous tumor cells are arguably the best source of TAA for cancer vaccine development, limitations plus the major time and expense required for the approval of each patient's vaccine by the appropriate regulatory agencies severely limits the development of this type of immunization approach.

To overcome some of these problems, basic and clinical investigators have explored other alternatives: namely, allogeneic tumor cell vaccines, tumor-APC fusion strategies, and mixed autologous-allogeneic tumor vaccines. The allogeneic approach is very attractive because it would allow the produced vaccine to be stored and ready for use when needed for the patient's immunization. Moreover, because many TAA seem to be shared among different patients' tumors [104–106], allogeneic vaccines, similar to autologous vaccines and in contrast with peptide vaccines, may allow bypassing the need to identify tumor antigens that actually are not known for the most common cancers. Finally, the efficacy of allogeneic vaccines has been established in preclinical models [93, 107, 108]. Several human studies using this approach recently have been initiated and/or reported [99–102, 109].

Jaffee et al. conducted a phase I trial of safety and immune activation in 14 patients with stage II or stage III pancreatic adenocarcinoma who underwent tumor resection followed by vaccination with two allogeneic pancreatic cancer cell lines [101]. The first vaccination occurred 8 weeks after the resection of the primary tumor followed by adjuvant chemoradiation. The second, third, and fourth vaccinations were given at weeks 40, 44, and 48, respectively. Six of 14 patients had no evidence of disease after completing the first vaccination and adjuvant chemoradiation and, therefore, were eligible to continue within the protocol. No systemic toxicities were observed. Four of five patients who received the highest dose of cells (50×10^7) were the only subjects to develop detectable serum levels of GM-CSF. Although efficacy was not the primary objective of this trial, four patients were disease-free for more than 25 months after diagnosis. Interestingly, these patients received some of the highest doses of allogeneic cells, and they also developed the largest DTH reactions against autologous tumor cells. The study demonstrated that the approach is safe and, at high doses, the allogeneic vaccine produced a remarkable DTH response against autologous tumor suggestive of antitumor immunity.

▶ TUMOR-APC HYBRIDS

A novel development in cancer vaccines is the use of tumor-APC fusion technology. The vaccine is produced by exposing tumor cells and APCs to polyethylene glycol (PEG) or electrical fields, which results in the generation of a tumor-APC hybrid. The rationale behind this approach is that the resulting hybrid will have the appropriate TAA derived from the tumor and the unparalleled costimulatory capabilities of the APCs.

Preclinical studies have provided the rationale for the use of cell hybrids in the

cancer vaccine setting [110–112]. More importantly, the tumor-APC strategy already has been associated with major clinical responses in patients with metastatic renal carcinoma [113]. In a pilot study, 17 patients received the vaccine SC in close proximity to inguinal lymph nodes. Six weeks later, patients received a booster immunization and underwent reevaluation. Patients without evidence of progressive disease continued with booster immunization every 3 months. The vaccine was well tolerated, with no significant toxicities or evidence of autoimmune disease. No patient had a DTH response after autologous tumor challenge before vaccination; however, 11 of 17 patients presented a positive DTH response after vaccination. Seven of the 11 patients who developed a DTH response had a complete or partial tumor response. In summary, 41% of the patients responded to the tumor-APC hybrid strategy with four CRs, two PRs, and one mixed response. With a median follow-up of 13 months, three of the four patients with CRs have remained without evidence of disease for up to 21 months. These impressive results in patients with advanced disease indicate that tumor-APC hybrid vaccination is a safe and effective therapy for metastatic renal carcinoma and warrants the development of prospective trials to further assess long-term efficacy.

Although the tumor-APC hybrid strategy has enormous potential, there are several questions that need to be addressed if this approach is to become widely used in clinical trials. For instance, which type of fusion technology must be used to generate the hybrids—PEG or electrofusion? What are the best APCs for the hybrid—mature cells that are better at presenting antigens or immature cells that may be better at trafficking to lymph nodes [114]? Which will be the best tumor source for the hybrid—autologous tumor cells with their potential for producing factors that negatively affect APC function and maturation or well-defined allogeneic-generic tumor cells for off-the-shelf use? Despite all these important and unanswered questions concerning this novel approach, the impressive results observed in early pilot studies encourage more clinical and basic research.

▶ IDIOTYPE VACCINATION

Immunoglobulin (Ig) molecules contain highly specific, unique peptide sequences in their variable regions at the antigen-combining sites in the complementary-determining regions. The variable regions of heavy and light chains combine to form the unique antigen recognition site of the Ig protein. These variable regions contain determinants that themselves can be recognized as antigens, or idiotypes. Non-Hodgkin's lymphomas are usually clonal proliferations of B cells synthesizing a single type of antibody molecule with a unique variable region that can serve as tumor-specific antigen [115] and, therefore, can be targeted for cancer vaccination. Follicular lymphomas also are associated with a characteristic translocation that brings the *bcl-2* gene on chromosome 18 under the transcriptional control of the Ig heavy-chain gene located in chromosome 14. This translocation, t(14-18), has been used as a molecular marker for minimal residual disease [116]. Most patients with follicular lymphoma in CR after conventional chemotherapy still have cells displaying the t(14-18) detectable by polymerase chain reaction (PCR) [117] and seem to be at increased risk of relapse.

The first clinical trial of idiotype vaccination included patients with low-grade follicular lymphoma in first remission [118]. Monitoring humoral and cellular responses to the vaccine revealed that 14 of 32 patients mounted predominately anti-idiotype humoral responses rather than T-cell proliferative responses to their autologous tumor idiotype protein. A recent analysis of these 32 patients demonstrated an improved clinical outcome for those patients who mounted a specific immune response [119]. A second pilot clinical trial using this approach in patients in CR after chemotherapy with the PACE regimen (prednisone, doxorubicin, cyclophosphamide, etoposide) has been reported [120]. Twenty chemotherapy-naïve patients with stage III/IV follicular lymphoma underwent lymph node collections and were treated with PACE to CR plus two additional cycles. After immune recovery, each patient received four monthly vaccinations with the lymphoma-associated Ig idiotype with KLH plus GM-CSF as adjuvant. Eleven of the 20 patients were found to have a detectable translocation in their primary tumors. All 11 patients had evidence of the malignant clone by PCR both at diagnosis and after chemotherapy, yet they were in complete clinical remission. After the vaccinations, 8 of the 11 patients achieved and sustained molecular remission. Moreover, $CD4^+$ tumor-specific cells also were induced by vaccination.

Although the long-term clinical relevance of molecular remission in follicular lymphoma remains to be ascertained [117, 121], it is clear that idiotype vaccination either reduces the tumor burden beyond that already achieved by chemotherapy or leads to the redistribution of residual tumor cells to sites other than peripheral blood. These two trials provide strong evidence for an antitumor effect of lymphoma-specific vaccination. A multicenter, prospective, randomized trial is being conducted to further evaluate whether idiotype vaccination results in long-term clinical benefit.

Although chemotherapy followed by idiotype vaccination with or without GM-CSF seems to be an effective regimen to immunize against lymphoma, several investigators are trying to improve this approach. One process under evaluation is the use of DCs pulsed with idiotype protein [77]. Results of the first clinical trial in patients with relapse follicular lymphoma have been encouraging, with evidence of both cellular immune responses and clinical responses in approximately 30% of patients. This promising outcome has prompted the use of DCs in patients in first remission [78] and has further energized the field with novel techniques trying to circumvent the cumbersome and costly process of generating an individually tailored vaccine. In this sense, recombinant idiotype proteins are now attainable for preclinical testing [122, 123] and one already has been the subject of a phase I-II clinical trial [122]. One alternative to the use of idiotype vaccine is the use of DCs pulsed with whole lymphoma lysate. This strategy may offer the opportunity to target potential yet undefined lymphoma antigens (other than idiotype), therefore widening the T-cell repertoire against lymphoma.

Another approach to idiotype vaccination for non-Hodgkin's lymphoma is based on animal and human studies, which have shown that, in an allogeneic setting, immunity to certain antigens could be transferred from the marrow donor to the patient [124–127]. The strategy entails the immunization of the immunologically competent and normal allogeneic donor with the idiotype vaccine derived from the recipient's tumor before harvesting the stem cells to be used in the transplant. This strategy may generate highly specific antilymphoma T cells that are capable of transferring antitumor-specific

immunity from marrow donor to recipient. This approach already has been used in a patient with multiple myeloma and demonstrated that a de novo anti-idiotype response could be transferred to the recipient [128, 129].

▶ CONCLUSIONS

Over the past few years there have been tremendous advances in the field of cellular and molecular immunology, improving our understanding of the interactions between the tumor-bearing host and the immune system. As we begin to widen our knowledge significantly, we will be in a position to better comprehend the barriers to successful immunotherapy for cancer. The development of therapeutic cancer vaccines is entering a new era in which specific molecules expressed on cells of the immune system or TAA are being targeted, with the hope of mounting an efficacious antitumor response. One of the reasons the immune system does not eradicate cancer cells seems to be that tumor cells do not display their antigens in ways that are recognized easily by CTLs. A growing understanding of the process of epitope enhancement is allowing the development of modified TAA with improved immunogenicity and objective clinical outcomes.

Ilya Ilyich Metchnikoff first described mononuclear phagocytic cells at the end of the 19th century. Since then, an impressive body of literature has documented the involvement of these cells in the host immune defense. The recognition of the fundamental role of APCs in the initiation of the immune response against tumors has become progressively clear; however, signals delivered by APCs may result in either activation or suppression of T-cell immunity, including the induction of peripheral tolerance. Strategies aimed at generating APCs that can polarize the immune response toward a Th1 phenotype have been developed successfully in preclinical models and now are being translated into the clinical arena [130]. The use of modified tumor cells (autologous and/or allogeneic) by themselves or in the format of a hybrid with APCs has erupted in the field, and very dramatic responses have been reported.

Despite the significant advances that are occurring in the field, cancer vaccine strategies need to be optimized to obtain more favorable clinical outcomes [131]. It is important that the type of patient is taken into account with this approach. Typically, phase I and some phase II clinical trials are performed on patients with advanced disease that have been exposed to several chemotherapy regimens. These patients may have a compromised antitumor response, and it is not known how much immunity is required to eradicate cancer from patients with advanced disease and a significant tumor burden. Perhaps cancer vaccines need to be tested in the setting of minimal residual disease or in patients with no evidence of disease after primary treatment. In these settings, clinicians will evaluate time to disease progression or relapse prevention, respectively. Careful consideration must be given to disease stabilization as a potential end-point of therapeutic cancer vaccines in patients with advanced disease.

In summary, it is critical that strategies being developed for cancer vaccines be based on clearly defined cellular and molecular targets. We must design rational combinations that act upon several cellular

types, including initiators of the immune response (APCs) and effector cells (T cells). Finally, thoughtful clinical trial design is imperative to evaluate cancer vaccines at this early stage. Given the abundance of concepts coming from the laboratories, the next decade presages unprecedented growth in the development of effective cancer vaccines.

▶ ACKNOWLEDGMENT

The author thanks *Dr. Dan L. Longo* for his critical comments, and *Ms. Kathleen Marshall* for the illustrations.

Disclaimer: The views expressed in this manuscript do not necessarily represent the views of the National Institutes of Health and/or the Department of Health and Human Services.

▶ REFERENCES

1. Papac RJ. Spontaneous regression of cancer. Cancer Treat Rev 1996;22:395–423.[Medline]
2. Lokich J. Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol 1997;20:416–418.[Medline]
3. Rock KL, Rothstein L, Benacerraf B. Analysis of the association of peptides of optimal length to class I molecules on the surface of cells. Proc Natl Acad Sci USA 1992;89:8918–8922.[Abstract]
4. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321–327.[Medline]
5. Tsang KY, Zaremba S, Nieroda CA et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982–990.[Abstract]
6. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997;18:267–268.[Medline]
7. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.[Abstract]
8. Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135–3143.[Abstract/Free Full Text]
9. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97:101–106.[Abstract/Free Full Text]
10. Osterborg A, Dyer MJ, Bunjes D. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997;15:1567–1574.[Abstract]
11. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of

humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–2648.[Abstract/Free Full Text]

12. Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485–1492.[Abstract]

13. Rosenberg SA, Yang JC, White DE et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998;228:307–319.[Medline]

14. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688–696.[Abstract]

15. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105–2116.[Abstract/Free Full Text]

16. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 1993;11:403–450.[Medline]

17. Steinman RM, Young JW. Signals arising from antigen-presenting cells. Curr Opin Immunol 1991;3:361–372.[Medline]

18. Hathcock KS, Laszlo G, Dickler HB et al. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 1993;262:905–907.[Medline]

19. Guinan EC, Gribben JG, Boussiotis VA et al. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994;84:3261–3282. [Abstract/Free Full Text]

20. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065–1068.[Medline]

21. Chen C, Nabavi N. In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2. Immunity 1994;1:147–154.[Medline]

22. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990;248:1349–1356.[Medline]

23. Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science 1995;270:932–933. [Free Full Text]

24. Staveley-O'Carroll K, Sotomayor E, Montgomery J et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 1998;95:1178–1183.[Abstract/Free Full Text]

25. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096–1103. [Medline]

26. Watson GA, Lopez DM. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses. J Immunol 1995;155:3124–3134. [Abstract]

27. Stoler DL, Chen N, Basik M et al. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci USA 1999;96:15121–15126. [Abstract/Free Full Text]

28. Fenton RG, Longo DL. Genetic instability and tumor cell variation: implications for immunotherapy. J Natl Cancer Inst 1995;87:241–243.[Medline]

29. Kastan MB, Zhan Q, el-Deiry WS et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587–597.[Medline]

30. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991–1045. [Abstract]

31. Fenton RG, Longo DL. Danger versus tolerance: paradigms for future studies of tumor-specific

cytotoxic T lymphocytes. J Natl Cancer Inst 1997;89:272–275.[Free Full Text]

32.　Ridge JP, Fuchs EJ, Matzinger P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 1996;271:1723–1726.[Abstract]

33.　Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994;64:529–564.[Medline]

34.　Coley WT. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 1893;105:487–511.

35.　Krieg AM, Wagner H. Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol Today 2000;21:521–526.[Medline]

36.　Tokunaga T, Yamamoto H, Shimada S et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984;72:955–962.[Medline]

37.　Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546–549.[Medline]

38.　Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J Immunol 1996;157:2116–2122.[Abstract]

39.　Sparwasser T, Vabulas RM, Villmow B et al. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol 2000;30:3591–3597.[Medline]

40.　Carpentier AF, Chen L, Maltonti F et al. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999;59:5429–5432. [Abstract/Free Full Text]

41.　Dow SW, Fradkin LG, Liggitt DH et al. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 1999;163:1552–1561.[Abstract/Free Full Text]

42.　Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER2/neu+ tumors. Cancer Res 1998;58:4902–4908.[Abstract]

43.　Sznol M. Emerging concepts in cancer vaccine development. PPO Updates 1999:13:1–14.

44.　van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643–1647.[Medline]

45.　Visseren MJ, van der Burg SH, van der Voort EI et al. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int J Cancer 1997;73:125–130.[Medline]

46.　Boon T, Gajewski TF, Coulie PG. From defined human tumor antigens to effective immunization? Immunol Today 1995;16:334–336.[Medline]

47.　Wang RF, Robbins PF, Kawakami Y et al. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995;181:799–804.[Abstract]

48.　Wang RF, Appella E, Kawakami Y et al. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996;184:2207–2216. [Abstract/Free Full Text]

49.　Brichard V, Van Pel A, Wolfel T et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489–495. [Abstract]

50.　Kawakami Y, Eliyahu S, Delgado CH et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458–6462.[Abstract]

51.　Kawakami Y, Eliyahu S, Delgado CH et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515–3519.[Abstract]

52. Moreau-Aubry A, Le Guiner S, Labarriere N at al. A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma. J Exp Med 2000;191:1617–1624. [Abstract/Free Full Text]

53. Wolfel T, Hauer M, Schneider J et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281–1284.[Medline]

54. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380–384.[Medline]

55. Cormier JN, Salgaller ML, Prevette T at al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37–44. [Medline]

56. Salgaller ML, Marincola FM, Cormier JN et al. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996;56:4749–4757.[Abstract]

57. Lewis JJ, Janetzki S, Schaed S et al. Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer 2000;87:391–398.[Medline]

58. Letsch A, Keilholz U, Schadendorf D et al. High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma. Int J Cancer 2000;87:659–664.[Medline]

59. Anichini A, Molla A, Mortarini R et al. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptidespecific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 1999;190:651–667.[Abstract/Free Full Text]

60. Parkhurst MR, Salgaller ML, Southwood S et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 1996;157:2539–2548.[Abstract]

61. Irvine KR, Parkhurst MR, Shulman ET at el. Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens. Cancer Res 1999;59:2536–2540. [Abstract/Free Full Text]

62. Livingston PO, Wong GY, Adluri S et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036–1044.[Abstract]

63. Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon alpha-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370–2380.[Abstract/Free Full Text]

64. Kirkwood JM, Ibrahim J, Lawson DH et al. High-dose interferon alpha-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 2001;19:1430–1436.[Abstract/Free Full Text]

65. Whiteside TL. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 1999;48:346–352.[Medline]

66. Ochoa AC, Longo DL. Alteration of signal transduction in T cells from cancer patients. Important Adv Oncol 1995;5:43–54.

67. Phan GQ, Wang E, Marincola FM. T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance. Expert Opin Biol Ther 2001;1:511–523.[Medline]

68. Ng CS, Novick AC, Tannenbaum CS et al. Mechanisms of immune evasion by renal cell carcinoma: tumor-induced T-lymphocyte apoptosis and NFkappaB suppression. Urology 2002;59:9–14.

69. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245–252.[Medline]

70. Nestle FO, Banchereau J, Hart D. Dendritic cells: on the move from bench to bedside. Nat Med

2001;7:761–765.[Medline]

71. Celluzzi CM, Mayordomo JI, Storkus WJ et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283–287.[Abstract]

72. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297–1302.[Medline]

73. Flamand V, Sornasse T, Thielemans K et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994;24:605–610.[Medline]

74. Hu X, Chakraborty NG, Sporn JR et al. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996;56:2479–2483.[Abstract]

75. Mukherji B, Chakraborty NG, Yamasaki S et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995;92:8078–8082.[Abstract]

76. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328–332.[Medline]

77. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52–58.[Medline]

78. Timmerman JM, Davis TA, Hsu FJ et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immunological responses in 26 patients. Blood 1999;94:385a.

79. Reichardt VL, Okada CY, Liso A et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma—a feasibility study. Blood 1999;93:2411–2419.[Abstract/Free Full Text]

80. Titzer S, Christensen O, Manzke O et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 2000;108:805–816. [Medline]

81. Morse MA, Deng Y, Coleman D et al. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999;5:1331–1338.[Abstract/Free Full Text]

82. Murphy G, Tjoa B, Ragde H et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371–380.[Medline]

83. Tjoa BA, Simmons SJ, Bowes VA et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998;36:39–44.[Medline]

84. Tjoa BA, Simmons SJ, Elgamal A et al. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 1999;40:125–129.[Medline]

85. Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894–3903.[Abstract/Free Full Text]

86. Burch PA, Breen JK, Buckner JC et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000;6:2175–2182. [Abstract/Free Full Text]

87. Yu JS, Wheeler CJ, Zeltzer PM et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001;61:842–847.[Abstract/Free Full Text]

88. McIllmurray MB, Embleton MJ, Reeves WG et al. Controlled trial of active immunotherapy in management of stage IIB malignant melanoma. Br Med J 1977;1:540– 542.[Medline]

89. Livingston PO, Takeyama H, Pollack MS et al. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells. Int J Cancer 1983;31:567–575. [Medline]

90. Livingston PO, Watanabe T, Shiku H et al. Serological response of melanoma patients receiving

melanoma cell vaccines. I. Autologous cultured melanoma cells. Int J Cancer 1982;30:413–422. [Medline]

91. Vermorken JB, Claessen AM, van Tinteren H et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999;353:345–350.[Medline]

92. Harris JE, Ryan L, Hoover Jr HC et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000;18:148–157.[Abstract/Free Full Text]

93. Fenton RG, Turcovski-Corrales SM, Taub DD. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines. J Immunother 1998;21:95–108.[Medline]

94. Fearon ER, Pardoll DM, Itaya T et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397–403.[Medline]

95. Golumbek PT, Lazenby AJ, Levitsky HI et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713–716.[Medline]

96. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:368–370.[Medline]

97. Plautz GE, Yang ZY, Wu BY et al. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 1993;90:4645–4649.[Abstract]

98. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539–3543.[Abstract]

99. Fenton RT, Sznol M, Luster DG et al. A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401. Hum Gene Ther 1995;6:87–106.[Medline]

100. Simons JW, Jaffee EM, Weber CE et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997;57:1537–1546.[Abstract]

101. Jaffee EM, Hruban RH, Biedrzycki B et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145–156.[Abstract/Free Full Text]

102. Newton DA, Acierno PM, Metts MC et al. Semiallogeneic cancer vaccines formulated with granulocyte-macrophage colony-stimulating factor for patients with metastatic gastrointestinal adenocarcinomas: a pilot phase I study. J Immunother 2001;24:19–26.[Medline]

103. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503–512.[Medline]

104. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996;183:725–729.[Medline]

105. Rosenberg SA, Kawakami Y, Robbins PF et al. Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv Cancer Res 1996;70:145–177.[Medline]

106. Brossart P, Heinrich KS, Stuhler G et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999;93:4309–4317.[Abstract/Free Full Text]

107. Toes RE, Blom RJ, van der Voort E et al. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 1996;56:3782–3787.[Abstract]

108. Thomas MC, Greten TF, Pardoll DM et al. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther 1998;9:835–843.[Medline]

109. Belli F, Arienti F, Sule-Suso J et al. Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. Cancer Immunol Immunother 1997;44:197–203.[Medline]

110. Gong J, Chen D, Kashiwaba M et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997;3:558–561.[Medline]

111. Gong J, Avigan D, Chen D et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 2000;97:2715–2718. [Abstract/Free Full Text]

112. Gong J, Chen D, Kashiwaba M et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 1998;95:6279–6283.[Abstract/Free Full Text]

113. Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000;6:332–336.[Medline]

114. Shu S, Cohen P. Tumor-dendritic cell fusion technology and immunotherapy strategies. J Immunother 2001;24:99–100.

115. Stevenson GT, Stevenson FK. Antibody to a molecularly-defined antigen confined to a tumour cell surface. Nature 1975;254:714–716.[Medline]

116. Lee MS, Chang KS, Cabanillas F et al. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science 1987;237:175–178.[Medline]

117. Gribben JG, Freedman A, Woo SD et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991;78:3275–3280.[Abstract]

118. Kwak LW, Campbell MJ, Czerwinski DK et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992;327:1209–1215.[Abstract]

119. Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long-term results of a clinical trial. Blood 1997;89:3129–3135. [Abstract/Free Full Text]

120. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999;5:1171–1177.[Medline]

121. Lopez-Guillermo A, Cabanillas F, McLaughlin P et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood 1998;91:2955–2960.[Abstract/Free Full Text]

122. Timmerman JM, Czerwinski D, van Beckhoven A et al. A phase I/II trial to evaluate the immunogenicity of recombinant idiotype protein vaccines for the treatment of non-Hodgkin's lymphoma. Blood 2000;96:578a.

123. Osterroth F, Garbe A, Fisch P et al. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells. Blood 2000;95:1342–1349.[Abstract/Free Full Text]

124. Grosse-Wilde H, Krumbacher K, Schuning F et al. Immune transfer studies in canine allogeneic marrow graft donor-recipient pairs. Transplantation 1986;42:64–67.[Medline]

125. Starling KA, Falletta JM, Fernbach DJ. Immunologic chimerism as evidence of bone marrow graft acceptance in an identical twin with acute lymphocytic leukemia. Exp Hematol 1975;3:244–248. [Medline]

126. Lum LG, Munn NA, Schanfield M et al. The detection of specific antibody formation to recall antigens after human bone marrow transplantation. Blood 1986;67:582–587.[Abstract]

127. Lum LG, Seigneuret MC, Storb R. The transfer of antigen-specific humoral immunity from marrow donors to marrow recipients. J Clin Immunol 1986;6:389–396.[Medline]

128. Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1993;345:1016–1020.

129. Massaia M, Borrione P, Battaglio S et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999;94:673–683. [Abstract/Free Full Text]

130. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol

2000;1:199–205.[Medline]
131. Disis ML, Schiffman K. Issues on clinical applications of cancer vaccines. J Immunother 2001;24:104–105.

▶ Abstract of this Article
▶ **Reprint (PDF) Version of this Article**
▶ **CME:** Take the course for this article:
   Cancer Vaccines
▶ Similar articles found in:
   The Oncologist Online
   PubMed
▶ PubMed Citation
▶ Search Medline for articles by:
   Espinoza-Delgado, I.
▶ Download to Citation Manager